Co-chaperones such as Aha1 can colocalize with Tau and had been identified as potentially interesting drug targets, but this is not reflected in altered levels in the AD proteome (Figure 5B; Shelton et al., 2017; Singh et al., 2020). This evidence concerns the gene MAPT and Alzheimer disease.